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Statins for primary prevention of cardiovascular disease 
     
In 1992 one of us called for a moratorium on the use of cholesterol lowering drugs in primary 
prevention published in the BMJ.1 At this time large statin trials had not been completed.  When the 
trials appeared it was clear that there were benefits at lower thresholds of coronary heart disease 
risk than was the case for earlier treatments. In 2011 our Cochrane Review on statins for primary 
prevention of cardiovascular disease concluded that statins should be used with caution for people 
at low cardiovascular risk.2 By 2013, with evidence from new trials and a re-analysis of the individual 
patient data from the Cholesterol Treatment Trialists 2012 report, our updated Cochrane review 
concluded that the evidence now supported use of statins for primary prevention in people at low 
risk of cardiovascular disease. 3 
 
John Maynard Keynes (may have) said “When my information changes, I alter my conclusions. What 
do you do, sir?”   A major strength of Cochrane reviews is updating in light of new evidence.  Fiona 
Godlee has called for the Chief Medical Officer (CMO) to initiate an independent inquiry into statins 
that would need to be international, authoritative, independent of conflicts of interest, transparent 
and patient centred. 4 Cochrane reviews on statins would appear to meet Godlee’s requirements 
but, curiously, are ignored.  The CMO, who supports the Cochrane Collaboration, will not overlook 
the value of using the resources she invests in to make decisions on health policy.  Is it not time for 
Godlee to change her mind? 
 
Shah Ebrahim, London School of Hygiene & Tropical Medicine  
&  
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